Sign In
Buy RVMD
$155.99
+4.68 (+3.09%)
At Close: Jun 03, 2026
Revolution Medicines, Inc. (RVMD) Discusses Positive Clinical Results and Implications for Metastatic Pancreatic Cancer Treatment Transcript
RVMD Stock Rises on Detailed Results From Pancreatic Cancer Study
10:16am, Monday, 01'st Jun 2026
Revolution Medicines jumps after detailed phase III data show daraxonrasib cuts death risk by 60% and doubles median survival in treated pancreatic cancer.
Revolution Medicines Jumps 12% As Cancer Drug Data Strengthens Case
09:26am, Monday, 01'st Jun 2026
Revolution Medicines (RVMD) moved higher in US premarket trading after fresh data added more weight to the story around daraxonrasib, its experimental pancreati
Revolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits Near All-Time Highs
10:43pm, Sunday, 31'st May 2026
Few cancers have proven as difficult to treat as pancreatic cancer, making any sign of a survival breakthrough a major event for both patients and investors.
Results simultaneously published in The New England Journal of Medicine Results simultaneously published in The New England Journal of Medicine
VHT vs. XBI: Vanguard Health Care ETF Tops SPDR Biotech in Yield and Cost
08:07am, Thursday, 28'th May 2026
Expense ratios, yield, and sector breadth set these healthcare ETFs apart-see how their risk profiles and portfolio strategies compare.
Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation
04:05pm, Thursday, 21'st May 2026
REDWOOD CITY, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ca
GraniteShares Files High-Octane 2X ETFs Tied To Nuclear, AI, Biotech Momentum Stocks
09:50am, Tuesday, 19'th May 2026
GraniteShares has filed with the U.S. Securities and Exchange Commission to launch three new leveraged single-stock ETFs tied to high-volatility themes spanning nuclear energy, AI infrastructure and b
Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report
11:47am, Friday, 15'th May 2026
U.S. cancer centers are moving quickly to enroll patients in an expanded access program for a pancreatic cancer drug developed by Revolution Medicines Inc. (NASDAQ:RVMD) after clinical trial results s
US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug
06:04am, Thursday, 14'th May 2026
U.S. cancer centers are scrambling to enroll patients in an early access program for a highly promising pancreatic cancer drug from Revolution Medicines while they await what they hope will be a sp
Small-Cap ETF Showdown: Schwab's SCHA vs. iShares' IJR
11:13am, Monday, 11'th May 2026
Expense ratios, diversification, and sector tilts set these two small-cap ETFs apart. Explore how their strategies impact risk and long-term performance.
RVMD Reports Wider-Than-Expected Loss in Q1, Raises '26 Expense View
01:50pm, Thursday, 07'th May 2026
Revolution Medicines posts a wider Q1 loss and raises its 2026 expense outlook as R&D and commercial prep costs climb.
Data contributed to the scientific and clinical rationale for RASolute 302, a pivotal Phase 3 trial in second line treatment of patients with metastatic pancreatic cancer Data contributed to the scien
Promising Revolution Medicines pancreatic cancer drug has high rate of mostly manageable side effects
05:01pm, Wednesday, 06'th May 2026
An experimental drug from Revolution Medicines that nearly doubled survival time for patients with advanced pancreas cancer in clinical trials comes with a high rate of mostly low-grade side eff
Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress
04:02pm, Wednesday, 06'th May 2026
Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; detailed results will be presented in upcoming ASCO Plenary p
